• Revised MRPs of 1,364 anti-cancer formulations take effect from November 9.
• The revised prices cover 121 drugs reported by 85 pharmaceutical companies.
• A total of 679 brands have reported price reductions exceeding 50 per cent.
• Consumers are expected to save ₹3,540.38 crore annually.

GG News Bureau
New Delhi, 9th Nov: The anti-cancer drug prices of 1,364 formulations have been revised with effect from November 9, following the National Pharmaceutical Pricing Authority’s (NPPA) decision to cap trade margins on 137 anti-cancer drugs. The move is expected to generate annual savings of ₹3,540.38 crore for consumers.

The NPPA, functioning under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, took the decision based on recommendations made by an Expert Committee constituted by the Directorate General of Health Services (DGHS), Ministry of Health and Family Welfare, on October 17, 2026.

According to the latest figures reported by the regulator, as of November 8, a total of 85 pharmaceutical companies had reported revised maximum retail prices (MRPs) for 1,364 anti-cancer formulations covering 121 drugs.

Of these, 679 brands reported price reductions of more than 50 per cent. The highest reported reduction in MRP stands at 96.45 per cent.

The revised prices are aimed at making cancer medicines more affordable and reducing the financial burden on patients and their families. The estimated annual savings from the price reductions stand at ₹3,540.38 crore.

Consumers can check the revised MRP printed on medicine packs and verify prices through the Pharma Sahi Daam mobile application or the NPPA website.

The regulator has also clarified that no chemist or hospital pharmacy can charge more than the revised MRP. Consumers facing overcharging or other price-related issues can register complaints through the Pharma Jan Samadhan portal or contact the NPPA helpline at 1800-111-255.